GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This clinical trial will evaluate the safety, tolerability and effectiveness of topical
GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.